Advances in Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency

Immunology and Allergy Clinics of North America

Volumn 28, Issue 2, 2008, Pages 439-456

  Gennery, Andrew R ^a,b   Cant, Andrew J ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BASILIXIMAB; BUSULFAN; CALCINEURIN INHIBITOR; CASPOFUNGIN; CD3 ANTIBODY; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFIBROTIDE; FOSCARNET; GANCICLOVIR; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; POSACONAZOLE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VORICONAZOLE;

B LYMPHOCYTE; BACTERIAL INFECTION; DENDRITIC CELL; DISEASE SEVERITY; EPSTEIN BARR VIRUS; GENETIC DISORDER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; INNATE IMMUNITY; NATURAL KILLER CELL; PHAGOCYTE; PHAGOCYTE DYSFUNCTION; PHENOTYPE; PHOTOTHERAPY; PRIORITY JOURNAL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE; TISSUE TYPING; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; VEIN OCCLUSION; VIRUS INFECTION; WISKOTT ALDRICH SYNDROME;

CD40 LIGAND; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; SEVERE COMBINED IMMUNODEFICIENCY; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WISKOTT-ALDRICH SYNDROME;

EID: 42149155983     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2008.01.006     Document Type: Review

References (73)

1. Geha R.S., Notarangelo L.D., Casanova J.L., et al., International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 120 4 (2007) 776-794
2. Ehl S., Schwarz K., Enders A., et al. A variant of SCID with specific immune responses and predominance of gamma delta T cells. J Clin Invest 115 11 (2005) 3140-3148
3. Moshous D., Pannetier C., Chasseval Rd R., et al. Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J Clin Invest 111 3 (2003) 381-387
4. Sumegi J., Huang D., Lanyi A., et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 96 9 (2000) 3118-3125
5. Winkelstein J.A., Marino M.C., Johnston Jr. R.B., et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 79 3 (2000) 155-169
6. Levy J., Espanol-Boren T., Thomas C., et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 131 1 Pt 1 (1997) 47-54
7. Imai K., Morio T., Zhu Y., et al. Clinical course of patients with WASP gene mutations. Blood 103 2 (2004) 456-464
8. Dale D.C., Cottle T.E., Fier C.J., et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 72 2 (2003) 82-93
9. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 5644 (2003) 415-419
10. Aiuti A., Cassani B., Andolfi G., et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 117 8 (2007) 2233-2240
11. Cale C.M., Jones A.M., and Goldblatt D. Follow up of patients with chronic granulomatous disease diagnosed since 1990. Clin Exp Immunol 120 2 (2000) 351-355
12. Antoine C., Müller S., Cant A., et al., European Group for Blood and Marrow Transplantation; European Society for Immunodeficiency. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 361 9357 (2003) 553-560
13. Grunebaum E., Mazzolari E., Porta F., et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 295 5 (2006) 508-518
14. Dalal I., Reid B., Doyle J., et al. Matched unrelated bone marrow transplantation for combined immunodeficiency. Bone Marrow Transplant 25 6 (2000) 613-621
15. Rao K., Amrolia P.J., Jones A., et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 105 2 (2005) 879-885
16. Jillella A.P., Shafer D., Klumpp T.R., et al. Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism. Am J Hematol 82 6 (2007) 419-426
17. Slatter M.A., Bhattacharya A., Abinun M., et al. Outcome of boost haemopoietic stem cell transplant for decreased donor chimerism or graft dysfunction in primary immunodeficiency. Bone Marrow Transplant 35 7 (2005) 683-689
18. Booth C., Ribeil J.A., Audat F., et al. CD34 stem cell top-ups without conditioning after initial haematopoietic stem cell transplantation for correction of incomplete haematopoietic and immunological recovery in severe congenital immunodeficiencies. Br J Haematol 135 4 (2006) 533-537
19. Cohen J., Gandhi M., Naik P., et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 129 2 (2005) 229-239
20. Kampmann B., Cubitt D., Walls T., et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol 130 4 (2005) 595-603
21. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110 4 (2007) 1123-1131
22. Karlsson H., Brewin J., Kinnon C., et al. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens. J Immunother (1997) 30 5 (2007) 544-556
23. Rodriguez V., Anderson P.M., Trotz B.A., et al. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatr Blood Cancer 49 2 (2007) 212-215
24. Jacobsohn D.A., Chen A.R., Zahurak M., et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol 25 27 (2007) 4255-4261
25. Biagi E., Di Biaso I., Leoni V., et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 84 1 (2007) 31-39
26. Zwaveling J., den Hartigh J., Lankester A.C., et al. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Anticancer Drugs 17 9 (2006) 1099-1105
27. Ryu S.G., Lee J.H., Choi S.J., et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant 13 9 (2007) 1095-1105
28. Corbacioglu S., Greil J., Peters C., et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 33 2 (2004) 189-195
29. Corbacioglu S., Hönig M., Lahr G., et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant 38 8 (2006) 547-553
30. Dignan F., Gujral D., Ethell M., et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 40 1 (2007) 79-82
31. Gennery A.R., and Cant A.J. Cord blood stem cell transplantation in primary immune deficiencies. Curr Opin Allergy Clin Immunol 7 6 (2007) 528-534
32. Bhattacharya A., Slatter M.A., Chapman C.E., et al. Single centre experience of umbilical cord stem cell transplantation for primary immunodeficiency. Bone Marrow Transplant 36 4 (2005) 295-299
33. Pipes B.L., Tsang T., Peng S.X., et al. Telomere length changes after umbilical cord blood transplant. Transfusion 46 6 (2006) 1038-1043
34. Amrolia P.J., Muccioli-Casadei G., Huls H., et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108 6 (2006) 1797-1808
35. Buckley R.H., Schiff S.E., Schiff R.I., et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340 7 (1999) 508-516
36. Myers L.A., Patel D.D., Puck J.M., et al. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 99 3 (2002) 872-878
37. Korthäuer U., Graf D., Mages H.W., et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 361 6412 (1993) 539-541
38. Gennery A.R., Khawaja K., Veys P., et al. Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002. Blood 103 3 (2004) 1152-1157
39. Khawaja K., Gennery A.R., Flood T.J., et al. Bone marrow transplantation for CD40 ligand deficiency: a single centre experience. Arch Dis Child 84 6 (2001) 508-511
40. Lemahieu V., Gastier J.M., and Francke U. Novel mutations in the Wiskott-Aldrich syndrome protein gene and their effects on transcriptional, translational, and clinical phenotypes. Hum Mutat 14 1 (1999) 54-66
41. Pai S.Y., DeMartiis D., Forino C., et al. Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant 38 10 (2006) 671-679
42. Ozsahin H., Le Deist F., Benkerrou M., et al. Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center. J Pediatr 129 2 (1996) 238-244
43. Muñoz A., Olivé T., Martinez A., et al., Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON). Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON). Pediatr Hematol Oncol 24 6 (2007) 393-402
44. Filipovich A.H., Stone J.V., Tomany S.C., et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 97 6 (2001) 1598-1603
45. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., et al. Long-term outcome following hematopoietic stem cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and the European Group for Blood and Marrow Transplantation. Blood 111 (2008) 439-445
46. Horwitz M.E., Barrett A.J., Brown M.R., et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 344 12 (2001) 881-888
47. Seger R.A., Gungor T., Belohradsky B.H., et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 100 13 (2002) 4344-4350
48. Güngör T., Halter J., Klink A., et al. Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation 79 11 (2005) 1596-1606
49. Steele J.M., Sung L., Klaassen R., et al., Canadian Inherited Marrow Failure Registry. Disease progression in recently diagnosed patients with inherited marrow failure syndromes: a Canadian Inherited Marrow Failure Registry (CIMFR) report. Pediatr Blood Cancer 47 7 (2006) 918-925
50. Rosenberg P.S., Alter B.P., Bolyard A.A., et al., Severe Chronic Neutropenia International Registry. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 107 12 (2006) 4628-4635
51. Rosenberg P.S., Alter B.P., Link D.C., et al. Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. Br J Haematol 140 (2008) 210-213
52. Choi S.W., Boxer L.A., Pulsipher M.A., et al. Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation. Bone Marrow Transplant 35 5 (2005) 473-477
53. Patel D.D., Gooding M.E., Parrott R.E., et al. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 342 18 (2000) 1325-1332
54. Borghans J.A., Bredius R.G., Hazenberg M.D., et al. Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency. Blood 108 2 (2006) 763-769
55. Cavazzana-Calvo M., Carlier F., Le Deist F., et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood 109 10 (2007) 4575-4581
56. Mazzolari E., Forino C., Guerci S., et al. Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. J Allergy Clin Immunol 120 4 (2007) 892-899
57. Slatter M.A., Brigham K., Dickinson A.M., et al. Long-term immune reconstitution following anti-CD52-treated or anti-CD34-treated haematopoietic stem cell transplant for severe T lymphocyte immunodeficiency. J Allergy Clin Immunol 121 (2008) 361-367
58. Slatter M.A., Gennery A.R., Cheetham T.D., et al. Thyroid dysfunction after bone marrow transplantation for primary immunodeficiency without the use of total body irradiation in conditioning. Bone Marrow Transplant 33 9 (2004) 949-953
59. Grigg A.P., McLachlan R., Zaja J., et al. Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). Bone Marrow Transplant 26 10 (2000) 1089-1095
60. Kyriacou C., Kottaridis P.D., Eliahoo J., et al. Germ cell damage and Leydig cell insufficiency in recipients of nonmyeloablative transplantation for haematological malignancies. Bone Marrow Transplant 31 1 (2003) 45-50
61. Soubani A.O., and Uberti J.P. Bronchiolitis obliterans following haematopoietic stem cell transplantation. Eur Respir J 29 5 (2007) 1007-1019
62. Gennery A.R. Primary immunodeficiency syndromes associated with defective DNA double-strand break repair. Br Med Bull 77-78 (2006) 71-85
63. Torgerson T.R., and Ochs H.D. Regulatory T cells in primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol 7 6 (2007) 515-521
64. Worth A., Thrasher A.J., and Gaspar H.B. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol 133 2 (2006) 124-140
65. McDermott M.F., and Tschopp J. From inflammasomes to fevers, crystals and hypertension: how basic research explains inflammatory diseases. Trends Mol Med 13 9 (2007) 381-388
66. Rao A., Kamani N., Filipovich A., et al. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood 109 1 (2007) 383-385
67. Dimopoulou M.N., Gandhi S., Ghevaert C., et al. Successful treatment of autoimmune lymphoproliferative syndrome and refractory autoimmune thrombocytopenic purpura with a reduced intensity conditioning stem cell transplantation followed by donor lymphocyte infusion. Bone Marrow Transplant 40 6 (2007) 605-606
68. Gennery A.R., Slatter M.A., Bhattacharya A., et al. Bone marrow transplantation for Nijmegen breakage syndrome. J Pediatr Hematol Oncol 27 4 (2005) 239
69. Neven B., Valayannopoulos V., Quartier P., et al. Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med 356 26 (2007) 2700-2703
70. Ringdén O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 10 (2006) 1390-1397
71. Le Blanc K., Samuelsson H., Gustafsson B., et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21 8 (2007) 1733-1738
72. Ball L.M., Bernardo M.E., Roelofs H., et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110 7 (2007) 2764-2767
73. Seggewiss R., Loré K., Guenaga F.J., et al. Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood 110 1 (2007) 441-449